DALLAS, July 2, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Arena Pharmaceuticals Inc. (Nasdaq:ARNA). The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/ARNA
ARNA is trading above its 13-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.
Arena Pharmaceuticals Inc. (ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. The Company's drug candidate, lorcaserin hydrochloride (lorcaserin), is being investigated in a phase 3 clinical trial program for the treatment of obesity. It has a pipeline of compounds that target G protein-coupled receptors (GPCRs), and includes compounds being evaluated independently and with its partners, including Merck & Co. Inc. and Ortho-McNeil-Janssen Pharmaceuticals Inc. On January 9, 2008, the Company acquired from Siegfried Ltd. certain drug product facility assets, including a licensed production facility, fixtures, equipment, other personal property and real estate assets in Zofingen, Switzerland.
Message Board Search for ARNA: http://www.boardcentral.com/boards/ARNA
In the report, the analyst notes:
"ARNA reported a lower net loss in the first quarter of 2010 of $31.3 million, or $0.33 per share, compared to a net loss in the first quarter of 2009 of $50.6 million, or $0.68 per share.
"ARNA recently announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of ARNA and Eisai. Lorcaserin, which ARNA discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition."
To read the entire report visit: http://www.microstockprofit.com/lp/ARNA
See what investors are saying about ARNA at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.